サンプル依頼リスト カート
  • English
デフォルト表紙
市場調査レポート
商品コード
1799043

孤立性線維性腫瘍治療の世界市場

Solitary Fibrous Tumor Treatment

出版日
ページ情報
英文 279 Pages
納期
即日から翌営業日
適宜更新あり
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=149.79円
孤立性線維性腫瘍治療の世界市場
出版日: 2025年08月27日
発行: Global Industry Analysts, Inc.
ページ情報: 英文 279 Pages
納期: 即日から翌営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 目次
概要

孤立性線維性腫瘍治療の世界市場は2030年までに5,460万米ドルに達する見込み

2024年に4,390万米ドルと推定される孤立性線維性腫瘍治療の世界市場は、分析期間2024-2030年にCAGR 3.7%で成長し、2030年には5,460万米ドルに達すると予測されます。本レポートで分析したセグメントの1つである外科治療は、CAGR 3.5%を記録し、分析期間終了時には3,190万米ドルに達すると予測されます。放射線治療分野の成長率は、分析期間中CAGR 4.4%と推定されます。

米国市場は1,200万米ドルと推定、中国はCAGR6.8％で成長予測

米国の孤立性線維性腫瘍治療市場は、2024年に1,200万米ドルと推定されます。世界第2位の経済大国である中国は、2030年までに1,100万米ドルの市場規模に達すると予測され、分析期間2024-2030年のCAGRは6.8%です。その他の注目すべき地域別市場としては、日本とカナダがあり、分析期間中のCAGRはそれぞれ1.5％と2.9％と予測されています。欧州では、ドイツがCAGR 2.1%で成長すると予測されています。

世界の孤立性線維性腫瘍治療市場- 主要動向と促進要因まとめ

孤立性線維性腫瘍治療：精密腫瘍学がパラダイムを変える？

孤発性線維性腫瘍（SFT）は、良性または悪性の可能性があるまれな間葉系新生物であり、その予測不可能な性質は、診断、治療計画、および長期管理に重大な課題をもたらします。これらの腫瘍は胸膜に発生するのが最も一般的であるが、髄膜、腹部、四肢など様々な胸膜外部位にも同定されています。SFT管理における重要な動向は、診断精度の向上における病理組織学的解析と免疫組織化学マーカーの中心的役割です。遺伝的特徴としてNAB2-STAT6遺伝子融合が同定されたことで、診断が飛躍的に洗練され、将来の治療標的としてますます利用されるようになっています。治療プロトコールは、腫瘍の悪性度、大きさ、および転移の可能性に基づく個別化されたアプローチの必要性が各施設で認識されるにつれて、急速に進化しています。

外科的切除は、特に断端陰性が達成された場合、限局性腫瘍に対する第一の根治的選択肢であり続ける。しかしながら、高リスクの組織学的特徴や不完全切除の場合には、放射線療法や全身療法などの補助的治療が検討されています。限局しているが手術不可能な病変に対する定位体放射線治療（SBRT）や、断端陽性切除に対する術後補助放射線療法への関心が高まっています。化学療法の有効性は限られているが、テモゾロミド、ベバシズマブ、チロシンキナーゼ阻害剤などの併用療法が検討されています。個別化腫瘍学はまた、ゲノム・プロファイリングと次世代シークエンシングによって、特に再発・転移症例において標的治療に役立つ実用的な変異を発見することによって、その地位を確立しつつあります。

新たな治療法と診断法は患者の転帰を変えるか？

分子病理学および画像診断における最近の進歩は、孤立性線維性腫瘍の検出および層別化を著しく改善しつつあります。PET-CT、造影MRI、および動的造影画像は病期分類とモニタリングの標準となりつつあります。さらに、循環腫瘍DNA（ctDNA）アッセイやその他のリキッドバイオプシー法の開発は、非侵襲的な疾患サーベイランスや再発の早期発見に有望です。免疫療法、特にチェックポイント阻害剤もまた、進行性または切除不能な病像を有するSFT患者を対象として評価されています。まだ初期段階であるが、結果は有望であり、世界中で複数の臨床試験が開始されています。

さらに、分子マーカーに基づく患者特異的治療レジメンは、SFTのような希少軟部腫瘍の管理方法にパラダイムシフトをもたらしつつあります。腫瘍委員会や希少疾患登録は、集学的な議論を促進し、コンセンサス主導の治療計画によって転帰を改善しています。世界のSFTコホートから得られるデータが増えるにつれ、研究開発はリスクに基づいたアルゴリズムを開発し、最適な監視間隔、手術戦略、補助療法の選択肢を決定しています。このようなデータ主導の個別化により、長らく治療方針が曖昧であったSFTの治療展望が大きく変わりつつあります。

ニッチオンコロジー市場の成長の原動力は？

孤立性線維性腫瘍治療市場の成長は、診断能力の向上、臨床医の意識の高まり、標的医療や精密医療の進歩に関連するいくつかの要因によってもたらされます。主な要因の1つは、SFTを正確に同定し、組織学的に類似した腫瘍と区別することができる高度な診断モダリティの利用可能性と使用の増加です。これにより、より正確な病期分類と早期の治療開始が可能となりました。さらに、ゲノム解析ツールが臨床に導入されたことで、腫瘍生物学に基づいて治療法をカスタマイズできるようになり、患者の転帰が改善されるようになりました。

肉腫専門の治療センターや希少がんネットワークの設立も重要な要素です。これらの専門施設は、専門知識や実験的治療へのアクセスを向上させるだけでなく、患者登録や臨床試験パイプラインにも貢献しています。特に希少がんや軟部肉腫に関する研究費の増加は、薬剤開発の触媒となり、治療の選択肢を広げています。さらに、観察研究や長期追跡調査からデータが蓄積されるにつれて、予測モデルや治療アルゴリズムが臨床医のエビデンスに基づく意思決定に役立っています。これらの要素が相まって、世界中のSFT患者のための強固で進化した治療エコシステムの開発が推進されています。

セグメント

治療（手術治療、放射線療法治療、補助化学療法治療）、エンドユーザー（外来手術センターエンドユーザー、病院エンドユーザー、その他エンドユーザー）

調査対象企業の例

  • Aadi Bioscience, Inc.
  • ADC Therapeutics SA
  • Advenchen Laboratories LLC
  • Arog Pharmaceuticals
  • AVEO Pharmaceuticals
  • Bayer AG
  • BeOne Medicines（formerly BeiGene）
  • Bristol-Myers Squibb Co
  • Chia Tai Tianqing Pharma
  • Chugai Pharma France
  • CytRx
  • Epizyme, Inc.
  • Gradalis, Inc.
  • Incyte Corporation
  • Iovance Biotherapeutics
  • Nanobiotix（Nanobiotix SA）
  • Novartis AG
  • Philogen S.p.A.
  • Plus Therapeutics, Inc.
  • Telix Pharmaceuticals Ltd

AIインテグレーション

Global Industry Analystsは、有効な専門家コンテンツとAIツールによって、市場情報と競合情報を変革しています。

Global Industry Analystsは、一般的なLLMや業界固有のSLMにクエリーする代わりに、ビデオ記録、ブログ、検索エンジン調査、大量の企業、製品/サービス、市場データなど、世界中の専門家からキュレートされたコンテンツのリポジトリを構築しました。

関税影響係数

Global Industry Analystsは、本社の国、製造拠点、輸出入（完成品とOEM）に基づく企業の競争力の変化を予測しています。この複雑で多面的な市場力学は、売上原価（COGS）の増加、収益性の低下、サプライチェーンの再構築など、ミクロおよびマクロの市場力学の中でも特に競合他社に影響を与える見込みです。

目次

第1章 調査手法

第2章 エグゼクティブサマリー

  • 市場概要
  • 主要企業
  • 市場動向と促進要因
  • 世界市場の見通し

第3章 市場分析

  • 米国
  • カナダ
  • 日本
  • 中国
  • 欧州
  • フランス
  • ドイツ
  • イタリア
  • 英国
  • スペイン
  • ロシア
  • その他欧州
  • アジア太平洋
  • オーストラリア
  • インド
  • 韓国
  • その他アジア太平洋地域
  • ラテンアメリカ
  • アルゼンチン
  • ブラジル
  • メキシコ
  • その他ラテンアメリカ
  • 中東
  • イラン
  • イスラエル
  • サウジアラビア
  • アラブ首長国連邦
  • その他中東
  • アフリカ

第4章 競合

目次
Product Code: MCP39366

Global Solitary Fibrous Tumor Treatment Market to Reach US$54.6 Million by 2030

The global market for Solitary Fibrous Tumor Treatment estimated at US$43.9 Million in the year 2024, is expected to reach US$54.6 Million by 2030, growing at a CAGR of 3.7% over the analysis period 2024-2030. Surgery Treatment, one of the segments analyzed in the report, is expected to record a 3.5% CAGR and reach US$31.9 Million by the end of the analysis period. Growth in the Radiation Therapy Treatment segment is estimated at 4.4% CAGR over the analysis period.

The U.S. Market is Estimated at US$12.0 Million While China is Forecast to Grow at 6.8% CAGR

The Solitary Fibrous Tumor Treatment market in the U.S. is estimated at US$12.0 Million in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$11.0 Million by the year 2030 trailing a CAGR of 6.8% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 1.5% and 2.9% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 2.1% CAGR.

Global Solitary Fibrous Tumor Treatment Market - Key Trends & Drivers Summarized

Solitary Fibrous Tumor Treatment: Is Precision Oncology Changing the Paradigm?

Solitary fibrous tumors (SFTs) are rare mesenchymal neoplasms that may be benign or malignant, and their unpredictable nature presents significant challenges in diagnosis, treatment planning, and long-term management. These tumors most commonly arise in the pleura but have also been identified in various extrapleural sites such as the meninges, abdomen, and extremities. A key trend in SFT management is the central role of histopathological analysis and immunohistochemical markers in improving diagnostic accuracy. The identification of the NAB2-STAT6 gene fusion as a genetic hallmark has significantly refined diagnosis and is increasingly used as a target for future therapies. Treatment protocols are evolving rapidly as institutions recognize the need for individualized approaches based on tumor grade, size, and metastatic potential.

Surgical resection remains the primary curative option for localized tumors, especially when negative margins are achieved. However, in cases of high-risk histological features or incomplete excision, adjunctive treatments such as radiotherapy and systemic therapies are being explored. There is growing interest in stereotactic body radiotherapy (SBRT) for localized but inoperable lesions, and in adjuvant radiation for margin-positive resections. Chemotherapy has shown limited efficacy, but combination regimens involving temozolomide, bevacizumab, and tyrosine kinase inhibitors are under investigation. Personalized oncology is also making its mark through genomic profiling and next-generation sequencing to uncover actionable mutations that could inform targeted therapies, particularly in recurrent or metastatic cases.

Are Emerging Therapies and Diagnostics Reshaping Patient Outcomes?

Recent advancements in molecular pathology and imaging are significantly improving the detection and stratification of solitary fibrous tumors. PET-CT, MRI with contrast, and dynamic contrast-enhanced imaging are becoming standard for staging and monitoring. Additionally, the development of circulating tumor DNA (ctDNA) assays and other liquid biopsy methods offer promise for non-invasive disease surveillance and early detection of recurrence. Immunotherapy, particularly checkpoint inhibitors, is also being evaluated in SFT patients with aggressive or unresectable disease profiles. While still in early phases, results are encouraging and have sparked multiple clinical trials worldwide.

Further, patient-specific treatment regimens based on molecular markers are driving a paradigm shift in how rare soft-tissue tumors like SFT are managed. Tumor boards and rare disease registries are facilitating multi-disciplinary discussions and improving outcomes through consensus-driven treatment planning. As more data becomes available from global SFT cohorts, researchers are developing risk-based algorithms to determine optimal surveillance intervals, surgical strategies, and adjuvant therapy options. Such data-driven personalization is transforming the therapeutic outlook for a condition that has long suffered from ambiguous treatment pathways.

What Is Fueling the Growth in This Niche Oncology Market?

The growth in the solitary fibrous tumor treatment market is driven by several factors related to improved diagnostic capabilities, rising awareness among clinicians, and advancements in targeted and precision medicine. One primary driver is the increasing availability and use of advanced diagnostic modalities that can accurately identify SFTs and differentiate them from histologically similar tumors. This has led to more accurate staging and earlier treatment initiation. Additionally, the integration of genomic tools into clinical practice has empowered oncologists to customize therapies based on tumor biology, resulting in better patient outcomes.

The establishment of dedicated sarcoma treatment centers and rare cancer networks is another critical factor. These specialized facilities not only enhance access to expertise and experimental therapies but also contribute to patient registries and clinical trial pipelines. An increase in research funding, particularly into rare cancers and soft-tissue sarcomas, is catalyzing drug development and expanding treatment options. Furthermore, as data accumulates from observational studies and long-term follow-ups, predictive models and treatment algorithms are helping clinicians make evidence-based decisions. Together, these elements are driving the development of a robust and evolving treatment ecosystem for SFT patients worldwide.

SCOPE OF STUDY:

The report analyzes the Solitary Fibrous Tumor Treatment market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Treatment (Surgery Treatment, Radiation Therapy Treatment, Adjuvant Chemotherapy Treatment); End-User (Ambulatory Surgery Centers End-User, Hospitals End-User, Other End-Users)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 42 Featured) -

  • Aadi Bioscience, Inc.
  • ADC Therapeutics SA
  • Advenchen Laboratories LLC
  • Arog Pharmaceuticals
  • AVEO Pharmaceuticals
  • Bayer AG
  • BeOne Medicines (formerly BeiGene)
  • Bristol-Myers Squibb Co
  • Chia Tai Tianqing Pharma
  • Chugai Pharma France
  • CytRx
  • Epizyme, Inc.
  • Gradalis, Inc.
  • Incyte Corporation
  • Iovance Biotherapeutics
  • Nanobiotix (Nanobiotix SA)
  • Novartis AG
  • Philogen S.p.A.
  • Plus Therapeutics, Inc.
  • Telix Pharmaceuticals Ltd

AI INTEGRATIONS

We're transforming market and competitive intelligence with validated expert content and AI tools.

Instead of following the general norm of querying LLMs and Industry-specific SLMs, we built repositories of content curated from domain experts worldwide including video transcripts, blogs, search engines research, and massive amounts of enterprise, product/service, and market data.

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by increasing the Cost of Goods Sold (COGS), reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Influencer Market Insights
    • World Market Trajectories
    • Tariff Impact on Global Supply Chain Patterns
    • Solitary Fibrous Tumor Treatment - Global Key Competitors Percentage Market Share in 2025 (E)
    • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E)
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
    • Increasing Clinical Recognition of Rare Tumors Spurs Research and Diagnostic Efforts in SFT
    • Rising Use of Targeted Therapy and Tyrosine Kinase Inhibitors Propels Drug Development for SFT
    • Expansion of Genomic Profiling and Tumor Marker Identification Strengthens Precision Medicine Approaches
    • Advanced Imaging Modalities Improve Early Detection and Surgical Planning for Solitary Fibrous Tumors
    • Growing Role of Immunotherapy in Soft Tissue Sarcomas Generates Pipeline Activity in SFT Space
    • Clinical Trial Expansion for Rare Tumors Opens Funding and Access to Experimental Therapies
    • Surge in Tertiary Oncology Centers Enhances Access to Multimodal SFT Treatment Protocols
    • Digital Pathology and AI-Based Histology Support Early and Accurate SFT Diagnosis
    • Increased Advocacy for Rare Cancer Awareness Drives Inclusion in National Cancer Registries
    • Combination Therapy Regimens and Off-Label Use Trends Expand Offshoot Markets for Adjunct Treatments
    • Global Collaboration in Rare Disease Research Supports Regulatory Acceleration and Orphan Drug Status
    • Minimally Invasive Surgical Advancements Propel Demand for Improved Preoperative Planning Tools
    • Real-World Evidence Generation and Biomarker Discovery Sustain Long-Term Research and Investment
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Solitary Fibrous Tumor Treatment Market Analysis of Annual Sales in US$ for Years 2014 through 2030
    • TABLE 2: World Recent Past, Current & Future Analysis for Solitary Fibrous Tumor Treatment by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2024 through 2030 and % CAGR
    • TABLE 3: World Historic Review for Solitary Fibrous Tumor Treatment by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 4: World 16-Year Perspective for Solitary Fibrous Tumor Treatment by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2014, 2025 & 2030
    • TABLE 5: World Recent Past, Current & Future Analysis for Surgery Treatment by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2024 through 2030 and % CAGR
    • TABLE 6: World Historic Review for Surgery Treatment by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 7: World 16-Year Perspective for Surgery Treatment by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 8: World Recent Past, Current & Future Analysis for Radiation Therapy Treatment by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2024 through 2030 and % CAGR
    • TABLE 9: World Historic Review for Radiation Therapy Treatment by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 10: World 16-Year Perspective for Radiation Therapy Treatment by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 11: World Recent Past, Current & Future Analysis for Adjuvant Chemotherapy Treatment by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2024 through 2030 and % CAGR
    • TABLE 12: World Historic Review for Adjuvant Chemotherapy Treatment by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 13: World 16-Year Perspective for Adjuvant Chemotherapy Treatment by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 14: World Recent Past, Current & Future Analysis for Ambulatory Surgery Centers End-User by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2024 through 2030 and % CAGR
    • TABLE 15: World Historic Review for Ambulatory Surgery Centers End-User by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 16: World 16-Year Perspective for Ambulatory Surgery Centers End-User by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 17: World Recent Past, Current & Future Analysis for Hospitals End-User by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2024 through 2030 and % CAGR
    • TABLE 18: World Historic Review for Hospitals End-User by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 19: World 16-Year Perspective for Hospitals End-User by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 20: World Recent Past, Current & Future Analysis for Other End-Users by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2024 through 2030 and % CAGR
    • TABLE 21: World Historic Review for Other End-Users by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 22: World 16-Year Perspective for Other End-Users by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030

III. MARKET ANALYSIS

  • UNITED STATES
    • Solitary Fibrous Tumor Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)
    • TABLE 23: USA Recent Past, Current & Future Analysis for Solitary Fibrous Tumor Treatment by Treatment - Surgery Treatment, Radiation Therapy Treatment and Adjuvant Chemotherapy Treatment - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 24: USA Historic Review for Solitary Fibrous Tumor Treatment by Treatment - Surgery Treatment, Radiation Therapy Treatment and Adjuvant Chemotherapy Treatment Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 25: USA 16-Year Perspective for Solitary Fibrous Tumor Treatment by Treatment - Percentage Breakdown of Value Sales for Surgery Treatment, Radiation Therapy Treatment and Adjuvant Chemotherapy Treatment for the Years 2014, 2025 & 2030
    • TABLE 26: USA Recent Past, Current & Future Analysis for Solitary Fibrous Tumor Treatment by End-user - Ambulatory Surgery Centers End-User, Hospitals End-User and Other End-Users - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 27: USA Historic Review for Solitary Fibrous Tumor Treatment by End-user - Ambulatory Surgery Centers End-User, Hospitals End-User and Other End-Users Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 28: USA 16-Year Perspective for Solitary Fibrous Tumor Treatment by End-user - Percentage Breakdown of Value Sales for Ambulatory Surgery Centers End-User, Hospitals End-User and Other End-Users for the Years 2014, 2025 & 2030
  • CANADA
    • TABLE 29: Canada Recent Past, Current & Future Analysis for Solitary Fibrous Tumor Treatment by Treatment - Surgery Treatment, Radiation Therapy Treatment and Adjuvant Chemotherapy Treatment - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 30: Canada Historic Review for Solitary Fibrous Tumor Treatment by Treatment - Surgery Treatment, Radiation Therapy Treatment and Adjuvant Chemotherapy Treatment Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 31: Canada 16-Year Perspective for Solitary Fibrous Tumor Treatment by Treatment - Percentage Breakdown of Value Sales for Surgery Treatment, Radiation Therapy Treatment and Adjuvant Chemotherapy Treatment for the Years 2014, 2025 & 2030
    • TABLE 32: Canada Recent Past, Current & Future Analysis for Solitary Fibrous Tumor Treatment by End-user - Ambulatory Surgery Centers End-User, Hospitals End-User and Other End-Users - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 33: Canada Historic Review for Solitary Fibrous Tumor Treatment by End-user - Ambulatory Surgery Centers End-User, Hospitals End-User and Other End-Users Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 34: Canada 16-Year Perspective for Solitary Fibrous Tumor Treatment by End-user - Percentage Breakdown of Value Sales for Ambulatory Surgery Centers End-User, Hospitals End-User and Other End-Users for the Years 2014, 2025 & 2030
  • JAPAN
    • Solitary Fibrous Tumor Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)
    • TABLE 35: Japan Recent Past, Current & Future Analysis for Solitary Fibrous Tumor Treatment by Treatment - Surgery Treatment, Radiation Therapy Treatment and Adjuvant Chemotherapy Treatment - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 36: Japan Historic Review for Solitary Fibrous Tumor Treatment by Treatment - Surgery Treatment, Radiation Therapy Treatment and Adjuvant Chemotherapy Treatment Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 37: Japan 16-Year Perspective for Solitary Fibrous Tumor Treatment by Treatment - Percentage Breakdown of Value Sales for Surgery Treatment, Radiation Therapy Treatment and Adjuvant Chemotherapy Treatment for the Years 2014, 2025 & 2030
    • TABLE 38: Japan Recent Past, Current & Future Analysis for Solitary Fibrous Tumor Treatment by End-user - Ambulatory Surgery Centers End-User, Hospitals End-User and Other End-Users - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 39: Japan Historic Review for Solitary Fibrous Tumor Treatment by End-user - Ambulatory Surgery Centers End-User, Hospitals End-User and Other End-Users Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 40: Japan 16-Year Perspective for Solitary Fibrous Tumor Treatment by End-user - Percentage Breakdown of Value Sales for Ambulatory Surgery Centers End-User, Hospitals End-User and Other End-Users for the Years 2014, 2025 & 2030
  • CHINA
    • Solitary Fibrous Tumor Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)
    • TABLE 41: China Recent Past, Current & Future Analysis for Solitary Fibrous Tumor Treatment by Treatment - Surgery Treatment, Radiation Therapy Treatment and Adjuvant Chemotherapy Treatment - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 42: China Historic Review for Solitary Fibrous Tumor Treatment by Treatment - Surgery Treatment, Radiation Therapy Treatment and Adjuvant Chemotherapy Treatment Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 43: China 16-Year Perspective for Solitary Fibrous Tumor Treatment by Treatment - Percentage Breakdown of Value Sales for Surgery Treatment, Radiation Therapy Treatment and Adjuvant Chemotherapy Treatment for the Years 2014, 2025 & 2030
    • TABLE 44: China Recent Past, Current & Future Analysis for Solitary Fibrous Tumor Treatment by End-user - Ambulatory Surgery Centers End-User, Hospitals End-User and Other End-Users - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 45: China Historic Review for Solitary Fibrous Tumor Treatment by End-user - Ambulatory Surgery Centers End-User, Hospitals End-User and Other End-Users Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 46: China 16-Year Perspective for Solitary Fibrous Tumor Treatment by End-user - Percentage Breakdown of Value Sales for Ambulatory Surgery Centers End-User, Hospitals End-User and Other End-Users for the Years 2014, 2025 & 2030
  • EUROPE
    • Solitary Fibrous Tumor Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)
    • TABLE 47: Europe Recent Past, Current & Future Analysis for Solitary Fibrous Tumor Treatment by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ for Years 2024 through 2030 and % CAGR
    • TABLE 48: Europe Historic Review for Solitary Fibrous Tumor Treatment by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 49: Europe 16-Year Perspective for Solitary Fibrous Tumor Treatment by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2014, 2025 & 2030
    • TABLE 50: Europe Recent Past, Current & Future Analysis for Solitary Fibrous Tumor Treatment by Treatment - Surgery Treatment, Radiation Therapy Treatment and Adjuvant Chemotherapy Treatment - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 51: Europe Historic Review for Solitary Fibrous Tumor Treatment by Treatment - Surgery Treatment, Radiation Therapy Treatment and Adjuvant Chemotherapy Treatment Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 52: Europe 16-Year Perspective for Solitary Fibrous Tumor Treatment by Treatment - Percentage Breakdown of Value Sales for Surgery Treatment, Radiation Therapy Treatment and Adjuvant Chemotherapy Treatment for the Years 2014, 2025 & 2030
    • TABLE 53: Europe Recent Past, Current & Future Analysis for Solitary Fibrous Tumor Treatment by End-user - Ambulatory Surgery Centers End-User, Hospitals End-User and Other End-Users - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 54: Europe Historic Review for Solitary Fibrous Tumor Treatment by End-user - Ambulatory Surgery Centers End-User, Hospitals End-User and Other End-Users Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 55: Europe 16-Year Perspective for Solitary Fibrous Tumor Treatment by End-user - Percentage Breakdown of Value Sales for Ambulatory Surgery Centers End-User, Hospitals End-User and Other End-Users for the Years 2014, 2025 & 2030
  • FRANCE
    • Solitary Fibrous Tumor Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)
    • TABLE 56: France Recent Past, Current & Future Analysis for Solitary Fibrous Tumor Treatment by Treatment - Surgery Treatment, Radiation Therapy Treatment and Adjuvant Chemotherapy Treatment - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 57: France Historic Review for Solitary Fibrous Tumor Treatment by Treatment - Surgery Treatment, Radiation Therapy Treatment and Adjuvant Chemotherapy Treatment Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 58: France 16-Year Perspective for Solitary Fibrous Tumor Treatment by Treatment - Percentage Breakdown of Value Sales for Surgery Treatment, Radiation Therapy Treatment and Adjuvant Chemotherapy Treatment for the Years 2014, 2025 & 2030
    • TABLE 59: France Recent Past, Current & Future Analysis for Solitary Fibrous Tumor Treatment by End-user - Ambulatory Surgery Centers End-User, Hospitals End-User and Other End-Users - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 60: France Historic Review for Solitary Fibrous Tumor Treatment by End-user - Ambulatory Surgery Centers End-User, Hospitals End-User and Other End-Users Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 61: France 16-Year Perspective for Solitary Fibrous Tumor Treatment by End-user - Percentage Breakdown of Value Sales for Ambulatory Surgery Centers End-User, Hospitals End-User and Other End-Users for the Years 2014, 2025 & 2030
  • GERMANY
    • Solitary Fibrous Tumor Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)
    • TABLE 62: Germany Recent Past, Current & Future Analysis for Solitary Fibrous Tumor Treatment by Treatment - Surgery Treatment, Radiation Therapy Treatment and Adjuvant Chemotherapy Treatment - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 63: Germany Historic Review for Solitary Fibrous Tumor Treatment by Treatment - Surgery Treatment, Radiation Therapy Treatment and Adjuvant Chemotherapy Treatment Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 64: Germany 16-Year Perspective for Solitary Fibrous Tumor Treatment by Treatment - Percentage Breakdown of Value Sales for Surgery Treatment, Radiation Therapy Treatment and Adjuvant Chemotherapy Treatment for the Years 2014, 2025 & 2030
    • TABLE 65: Germany Recent Past, Current & Future Analysis for Solitary Fibrous Tumor Treatment by End-user - Ambulatory Surgery Centers End-User, Hospitals End-User and Other End-Users - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 66: Germany Historic Review for Solitary Fibrous Tumor Treatment by End-user - Ambulatory Surgery Centers End-User, Hospitals End-User and Other End-Users Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 67: Germany 16-Year Perspective for Solitary Fibrous Tumor Treatment by End-user - Percentage Breakdown of Value Sales for Ambulatory Surgery Centers End-User, Hospitals End-User and Other End-Users for the Years 2014, 2025 & 2030
  • ITALY
    • TABLE 68: Italy Recent Past, Current & Future Analysis for Solitary Fibrous Tumor Treatment by Treatment - Surgery Treatment, Radiation Therapy Treatment and Adjuvant Chemotherapy Treatment - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 69: Italy Historic Review for Solitary Fibrous Tumor Treatment by Treatment - Surgery Treatment, Radiation Therapy Treatment and Adjuvant Chemotherapy Treatment Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 70: Italy 16-Year Perspective for Solitary Fibrous Tumor Treatment by Treatment - Percentage Breakdown of Value Sales for Surgery Treatment, Radiation Therapy Treatment and Adjuvant Chemotherapy Treatment for the Years 2014, 2025 & 2030
    • TABLE 71: Italy Recent Past, Current & Future Analysis for Solitary Fibrous Tumor Treatment by End-user - Ambulatory Surgery Centers End-User, Hospitals End-User and Other End-Users - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 72: Italy Historic Review for Solitary Fibrous Tumor Treatment by End-user - Ambulatory Surgery Centers End-User, Hospitals End-User and Other End-Users Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 73: Italy 16-Year Perspective for Solitary Fibrous Tumor Treatment by End-user - Percentage Breakdown of Value Sales for Ambulatory Surgery Centers End-User, Hospitals End-User and Other End-Users for the Years 2014, 2025 & 2030
  • UNITED KINGDOM
    • Solitary Fibrous Tumor Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)
    • TABLE 74: UK Recent Past, Current & Future Analysis for Solitary Fibrous Tumor Treatment by Treatment - Surgery Treatment, Radiation Therapy Treatment and Adjuvant Chemotherapy Treatment - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 75: UK Historic Review for Solitary Fibrous Tumor Treatment by Treatment - Surgery Treatment, Radiation Therapy Treatment and Adjuvant Chemotherapy Treatment Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 76: UK 16-Year Perspective for Solitary Fibrous Tumor Treatment by Treatment - Percentage Breakdown of Value Sales for Surgery Treatment, Radiation Therapy Treatment and Adjuvant Chemotherapy Treatment for the Years 2014, 2025 & 2030
    • TABLE 77: UK Recent Past, Current & Future Analysis for Solitary Fibrous Tumor Treatment by End-user - Ambulatory Surgery Centers End-User, Hospitals End-User and Other End-Users - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 78: UK Historic Review for Solitary Fibrous Tumor Treatment by End-user - Ambulatory Surgery Centers End-User, Hospitals End-User and Other End-Users Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 79: UK 16-Year Perspective for Solitary Fibrous Tumor Treatment by End-user - Percentage Breakdown of Value Sales for Ambulatory Surgery Centers End-User, Hospitals End-User and Other End-Users for the Years 2014, 2025 & 2030
  • SPAIN
    • TABLE 80: Spain Recent Past, Current & Future Analysis for Solitary Fibrous Tumor Treatment by Treatment - Surgery Treatment, Radiation Therapy Treatment and Adjuvant Chemotherapy Treatment - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 81: Spain Historic Review for Solitary Fibrous Tumor Treatment by Treatment - Surgery Treatment, Radiation Therapy Treatment and Adjuvant Chemotherapy Treatment Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 82: Spain 16-Year Perspective for Solitary Fibrous Tumor Treatment by Treatment - Percentage Breakdown of Value Sales for Surgery Treatment, Radiation Therapy Treatment and Adjuvant Chemotherapy Treatment for the Years 2014, 2025 & 2030
    • TABLE 83: Spain Recent Past, Current & Future Analysis for Solitary Fibrous Tumor Treatment by End-user - Ambulatory Surgery Centers End-User, Hospitals End-User and Other End-Users - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 84: Spain Historic Review for Solitary Fibrous Tumor Treatment by End-user - Ambulatory Surgery Centers End-User, Hospitals End-User and Other End-Users Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 85: Spain 16-Year Perspective for Solitary Fibrous Tumor Treatment by End-user - Percentage Breakdown of Value Sales for Ambulatory Surgery Centers End-User, Hospitals End-User and Other End-Users for the Years 2014, 2025 & 2030
  • RUSSIA
    • TABLE 86: Russia Recent Past, Current & Future Analysis for Solitary Fibrous Tumor Treatment by Treatment - Surgery Treatment, Radiation Therapy Treatment and Adjuvant Chemotherapy Treatment - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 87: Russia Historic Review for Solitary Fibrous Tumor Treatment by Treatment - Surgery Treatment, Radiation Therapy Treatment and Adjuvant Chemotherapy Treatment Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 88: Russia 16-Year Perspective for Solitary Fibrous Tumor Treatment by Treatment - Percentage Breakdown of Value Sales for Surgery Treatment, Radiation Therapy Treatment and Adjuvant Chemotherapy Treatment for the Years 2014, 2025 & 2030
    • TABLE 89: Russia Recent Past, Current & Future Analysis for Solitary Fibrous Tumor Treatment by End-user - Ambulatory Surgery Centers End-User, Hospitals End-User and Other End-Users - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 90: Russia Historic Review for Solitary Fibrous Tumor Treatment by End-user - Ambulatory Surgery Centers End-User, Hospitals End-User and Other End-Users Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 91: Russia 16-Year Perspective for Solitary Fibrous Tumor Treatment by End-user - Percentage Breakdown of Value Sales for Ambulatory Surgery Centers End-User, Hospitals End-User and Other End-Users for the Years 2014, 2025 & 2030
  • REST OF EUROPE
    • TABLE 92: Rest of Europe Recent Past, Current & Future Analysis for Solitary Fibrous Tumor Treatment by Treatment - Surgery Treatment, Radiation Therapy Treatment and Adjuvant Chemotherapy Treatment - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 93: Rest of Europe Historic Review for Solitary Fibrous Tumor Treatment by Treatment - Surgery Treatment, Radiation Therapy Treatment and Adjuvant Chemotherapy Treatment Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 94: Rest of Europe 16-Year Perspective for Solitary Fibrous Tumor Treatment by Treatment - Percentage Breakdown of Value Sales for Surgery Treatment, Radiation Therapy Treatment and Adjuvant Chemotherapy Treatment for the Years 2014, 2025 & 2030
    • TABLE 95: Rest of Europe Recent Past, Current & Future Analysis for Solitary Fibrous Tumor Treatment by End-user - Ambulatory Surgery Centers End-User, Hospitals End-User and Other End-Users - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 96: Rest of Europe Historic Review for Solitary Fibrous Tumor Treatment by End-user - Ambulatory Surgery Centers End-User, Hospitals End-User and Other End-Users Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 97: Rest of Europe 16-Year Perspective for Solitary Fibrous Tumor Treatment by End-user - Percentage Breakdown of Value Sales for Ambulatory Surgery Centers End-User, Hospitals End-User and Other End-Users for the Years 2014, 2025 & 2030
  • ASIA-PACIFIC
    • Solitary Fibrous Tumor Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)
    • TABLE 98: Asia-Pacific Recent Past, Current & Future Analysis for Solitary Fibrous Tumor Treatment by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ for Years 2024 through 2030 and % CAGR
    • TABLE 99: Asia-Pacific Historic Review for Solitary Fibrous Tumor Treatment by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 100: Asia-Pacific 16-Year Perspective for Solitary Fibrous Tumor Treatment by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2014, 2025 & 2030
    • TABLE 101: Asia-Pacific Recent Past, Current & Future Analysis for Solitary Fibrous Tumor Treatment by Treatment - Surgery Treatment, Radiation Therapy Treatment and Adjuvant Chemotherapy Treatment - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 102: Asia-Pacific Historic Review for Solitary Fibrous Tumor Treatment by Treatment - Surgery Treatment, Radiation Therapy Treatment and Adjuvant Chemotherapy Treatment Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 103: Asia-Pacific 16-Year Perspective for Solitary Fibrous Tumor Treatment by Treatment - Percentage Breakdown of Value Sales for Surgery Treatment, Radiation Therapy Treatment and Adjuvant Chemotherapy Treatment for the Years 2014, 2025 & 2030
    • TABLE 104: Asia-Pacific Recent Past, Current & Future Analysis for Solitary Fibrous Tumor Treatment by End-user - Ambulatory Surgery Centers End-User, Hospitals End-User and Other End-Users - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 105: Asia-Pacific Historic Review for Solitary Fibrous Tumor Treatment by End-user - Ambulatory Surgery Centers End-User, Hospitals End-User and Other End-Users Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 106: Asia-Pacific 16-Year Perspective for Solitary Fibrous Tumor Treatment by End-user - Percentage Breakdown of Value Sales for Ambulatory Surgery Centers End-User, Hospitals End-User and Other End-Users for the Years 2014, 2025 & 2030
  • AUSTRALIA
    • Solitary Fibrous Tumor Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2025 (E)
    • TABLE 107: Australia Recent Past, Current & Future Analysis for Solitary Fibrous Tumor Treatment by Treatment - Surgery Treatment, Radiation Therapy Treatment and Adjuvant Chemotherapy Treatment - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 108: Australia Historic Review for Solitary Fibrous Tumor Treatment by Treatment - Surgery Treatment, Radiation Therapy Treatment and Adjuvant Chemotherapy Treatment Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 109: Australia 16-Year Perspective for Solitary Fibrous Tumor Treatment by Treatment - Percentage Breakdown of Value Sales for Surgery Treatment, Radiation Therapy Treatment and Adjuvant Chemotherapy Treatment for the Years 2014, 2025 & 2030
    • TABLE 110: Australia Recent Past, Current & Future Analysis for Solitary Fibrous Tumor Treatment by End-user - Ambulatory Surgery Centers End-User, Hospitals End-User and Other End-Users - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 111: Australia Historic Review for Solitary Fibrous Tumor Treatment by End-user - Ambulatory Surgery Centers End-User, Hospitals End-User and Other End-Users Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 112: Australia 16-Year Perspective for Solitary Fibrous Tumor Treatment by End-user - Percentage Breakdown of Value Sales for Ambulatory Surgery Centers End-User, Hospitals End-User and Other End-Users for the Years 2014, 2025 & 2030
  • INDIA
    • Solitary Fibrous Tumor Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2025 (E)
    • TABLE 113: India Recent Past, Current & Future Analysis for Solitary Fibrous Tumor Treatment by Treatment - Surgery Treatment, Radiation Therapy Treatment and Adjuvant Chemotherapy Treatment - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 114: India Historic Review for Solitary Fibrous Tumor Treatment by Treatment - Surgery Treatment, Radiation Therapy Treatment and Adjuvant Chemotherapy Treatment Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 115: India 16-Year Perspective for Solitary Fibrous Tumor Treatment by Treatment - Percentage Breakdown of Value Sales for Surgery Treatment, Radiation Therapy Treatment and Adjuvant Chemotherapy Treatment for the Years 2014, 2025 & 2030
    • TABLE 116: India Recent Past, Current & Future Analysis for Solitary Fibrous Tumor Treatment by End-user - Ambulatory Surgery Centers End-User, Hospitals End-User and Other End-Users - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 117: India Historic Review for Solitary Fibrous Tumor Treatment by End-user - Ambulatory Surgery Centers End-User, Hospitals End-User and Other End-Users Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 118: India 16-Year Perspective for Solitary Fibrous Tumor Treatment by End-user - Percentage Breakdown of Value Sales for Ambulatory Surgery Centers End-User, Hospitals End-User and Other End-Users for the Years 2014, 2025 & 2030
  • SOUTH KOREA
    • TABLE 119: South Korea Recent Past, Current & Future Analysis for Solitary Fibrous Tumor Treatment by Treatment - Surgery Treatment, Radiation Therapy Treatment and Adjuvant Chemotherapy Treatment - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 120: South Korea Historic Review for Solitary Fibrous Tumor Treatment by Treatment - Surgery Treatment, Radiation Therapy Treatment and Adjuvant Chemotherapy Treatment Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 121: South Korea 16-Year Perspective for Solitary Fibrous Tumor Treatment by Treatment - Percentage Breakdown of Value Sales for Surgery Treatment, Radiation Therapy Treatment and Adjuvant Chemotherapy Treatment for the Years 2014, 2025 & 2030
    • TABLE 122: South Korea Recent Past, Current & Future Analysis for Solitary Fibrous Tumor Treatment by End-user - Ambulatory Surgery Centers End-User, Hospitals End-User and Other End-Users - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 123: South Korea Historic Review for Solitary Fibrous Tumor Treatment by End-user - Ambulatory Surgery Centers End-User, Hospitals End-User and Other End-Users Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 124: South Korea 16-Year Perspective for Solitary Fibrous Tumor Treatment by End-user - Percentage Breakdown of Value Sales for Ambulatory Surgery Centers End-User, Hospitals End-User and Other End-Users for the Years 2014, 2025 & 2030
  • REST OF ASIA-PACIFIC
    • TABLE 125: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Solitary Fibrous Tumor Treatment by Treatment - Surgery Treatment, Radiation Therapy Treatment and Adjuvant Chemotherapy Treatment - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 126: Rest of Asia-Pacific Historic Review for Solitary Fibrous Tumor Treatment by Treatment - Surgery Treatment, Radiation Therapy Treatment and Adjuvant Chemotherapy Treatment Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 127: Rest of Asia-Pacific 16-Year Perspective for Solitary Fibrous Tumor Treatment by Treatment - Percentage Breakdown of Value Sales for Surgery Treatment, Radiation Therapy Treatment and Adjuvant Chemotherapy Treatment for the Years 2014, 2025 & 2030
    • TABLE 128: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Solitary Fibrous Tumor Treatment by End-user - Ambulatory Surgery Centers End-User, Hospitals End-User and Other End-Users - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 129: Rest of Asia-Pacific Historic Review for Solitary Fibrous Tumor Treatment by End-user - Ambulatory Surgery Centers End-User, Hospitals End-User and Other End-Users Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 130: Rest of Asia-Pacific 16-Year Perspective for Solitary Fibrous Tumor Treatment by End-user - Percentage Breakdown of Value Sales for Ambulatory Surgery Centers End-User, Hospitals End-User and Other End-Users for the Years 2014, 2025 & 2030
  • LATIN AMERICA
    • Solitary Fibrous Tumor Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2025 (E)
    • TABLE 131: Latin America Recent Past, Current & Future Analysis for Solitary Fibrous Tumor Treatment by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ for Years 2024 through 2030 and % CAGR
    • TABLE 132: Latin America Historic Review for Solitary Fibrous Tumor Treatment by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 133: Latin America 16-Year Perspective for Solitary Fibrous Tumor Treatment by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2014, 2025 & 2030
    • TABLE 134: Latin America Recent Past, Current & Future Analysis for Solitary Fibrous Tumor Treatment by Treatment - Surgery Treatment, Radiation Therapy Treatment and Adjuvant Chemotherapy Treatment - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 135: Latin America Historic Review for Solitary Fibrous Tumor Treatment by Treatment - Surgery Treatment, Radiation Therapy Treatment and Adjuvant Chemotherapy Treatment Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 136: Latin America 16-Year Perspective for Solitary Fibrous Tumor Treatment by Treatment - Percentage Breakdown of Value Sales for Surgery Treatment, Radiation Therapy Treatment and Adjuvant Chemotherapy Treatment for the Years 2014, 2025 & 2030
    • TABLE 137: Latin America Recent Past, Current & Future Analysis for Solitary Fibrous Tumor Treatment by End-user - Ambulatory Surgery Centers End-User, Hospitals End-User and Other End-Users - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 138: Latin America Historic Review for Solitary Fibrous Tumor Treatment by End-user - Ambulatory Surgery Centers End-User, Hospitals End-User and Other End-Users Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 139: Latin America 16-Year Perspective for Solitary Fibrous Tumor Treatment by End-user - Percentage Breakdown of Value Sales for Ambulatory Surgery Centers End-User, Hospitals End-User and Other End-Users for the Years 2014, 2025 & 2030
  • ARGENTINA
    • TABLE 140: Argentina Recent Past, Current & Future Analysis for Solitary Fibrous Tumor Treatment by Treatment - Surgery Treatment, Radiation Therapy Treatment and Adjuvant Chemotherapy Treatment - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 141: Argentina Historic Review for Solitary Fibrous Tumor Treatment by Treatment - Surgery Treatment, Radiation Therapy Treatment and Adjuvant Chemotherapy Treatment Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 142: Argentina 16-Year Perspective for Solitary Fibrous Tumor Treatment by Treatment - Percentage Breakdown of Value Sales for Surgery Treatment, Radiation Therapy Treatment and Adjuvant Chemotherapy Treatment for the Years 2014, 2025 & 2030
    • TABLE 143: Argentina Recent Past, Current & Future Analysis for Solitary Fibrous Tumor Treatment by End-user - Ambulatory Surgery Centers End-User, Hospitals End-User and Other End-Users - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 144: Argentina Historic Review for Solitary Fibrous Tumor Treatment by End-user - Ambulatory Surgery Centers End-User, Hospitals End-User and Other End-Users Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 145: Argentina 16-Year Perspective for Solitary Fibrous Tumor Treatment by End-user - Percentage Breakdown of Value Sales for Ambulatory Surgery Centers End-User, Hospitals End-User and Other End-Users for the Years 2014, 2025 & 2030
  • BRAZIL
    • TABLE 146: Brazil Recent Past, Current & Future Analysis for Solitary Fibrous Tumor Treatment by Treatment - Surgery Treatment, Radiation Therapy Treatment and Adjuvant Chemotherapy Treatment - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 147: Brazil Historic Review for Solitary Fibrous Tumor Treatment by Treatment - Surgery Treatment, Radiation Therapy Treatment and Adjuvant Chemotherapy Treatment Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 148: Brazil 16-Year Perspective for Solitary Fibrous Tumor Treatment by Treatment - Percentage Breakdown of Value Sales for Surgery Treatment, Radiation Therapy Treatment and Adjuvant Chemotherapy Treatment for the Years 2014, 2025 & 2030
    • TABLE 149: Brazil Recent Past, Current & Future Analysis for Solitary Fibrous Tumor Treatment by End-user - Ambulatory Surgery Centers End-User, Hospitals End-User and Other End-Users - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 150: Brazil Historic Review for Solitary Fibrous Tumor Treatment by End-user - Ambulatory Surgery Centers End-User, Hospitals End-User and Other End-Users Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 151: Brazil 16-Year Perspective for Solitary Fibrous Tumor Treatment by End-user - Percentage Breakdown of Value Sales for Ambulatory Surgery Centers End-User, Hospitals End-User and Other End-Users for the Years 2014, 2025 & 2030
  • MEXICO
    • TABLE 152: Mexico Recent Past, Current & Future Analysis for Solitary Fibrous Tumor Treatment by Treatment - Surgery Treatment, Radiation Therapy Treatment and Adjuvant Chemotherapy Treatment - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 153: Mexico Historic Review for Solitary Fibrous Tumor Treatment by Treatment - Surgery Treatment, Radiation Therapy Treatment and Adjuvant Chemotherapy Treatment Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 154: Mexico 16-Year Perspective for Solitary Fibrous Tumor Treatment by Treatment - Percentage Breakdown of Value Sales for Surgery Treatment, Radiation Therapy Treatment and Adjuvant Chemotherapy Treatment for the Years 2014, 2025 & 2030
    • TABLE 155: Mexico Recent Past, Current & Future Analysis for Solitary Fibrous Tumor Treatment by End-user - Ambulatory Surgery Centers End-User, Hospitals End-User and Other End-Users - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 156: Mexico Historic Review for Solitary Fibrous Tumor Treatment by End-user - Ambulatory Surgery Centers End-User, Hospitals End-User and Other End-Users Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 157: Mexico 16-Year Perspective for Solitary Fibrous Tumor Treatment by End-user - Percentage Breakdown of Value Sales for Ambulatory Surgery Centers End-User, Hospitals End-User and Other End-Users for the Years 2014, 2025 & 2030
  • REST OF LATIN AMERICA
    • TABLE 158: Rest of Latin America Recent Past, Current & Future Analysis for Solitary Fibrous Tumor Treatment by Treatment - Surgery Treatment, Radiation Therapy Treatment and Adjuvant Chemotherapy Treatment - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 159: Rest of Latin America Historic Review for Solitary Fibrous Tumor Treatment by Treatment - Surgery Treatment, Radiation Therapy Treatment and Adjuvant Chemotherapy Treatment Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 160: Rest of Latin America 16-Year Perspective for Solitary Fibrous Tumor Treatment by Treatment - Percentage Breakdown of Value Sales for Surgery Treatment, Radiation Therapy Treatment and Adjuvant Chemotherapy Treatment for the Years 2014, 2025 & 2030
    • TABLE 161: Rest of Latin America Recent Past, Current & Future Analysis for Solitary Fibrous Tumor Treatment by End-user - Ambulatory Surgery Centers End-User, Hospitals End-User and Other End-Users - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 162: Rest of Latin America Historic Review for Solitary Fibrous Tumor Treatment by End-user - Ambulatory Surgery Centers End-User, Hospitals End-User and Other End-Users Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 163: Rest of Latin America 16-Year Perspective for Solitary Fibrous Tumor Treatment by End-user - Percentage Breakdown of Value Sales for Ambulatory Surgery Centers End-User, Hospitals End-User and Other End-Users for the Years 2014, 2025 & 2030
  • MIDDLE EAST
    • Solitary Fibrous Tumor Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2025 (E)
    • TABLE 164: Middle East Recent Past, Current & Future Analysis for Solitary Fibrous Tumor Treatment by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ for Years 2024 through 2030 and % CAGR
    • TABLE 165: Middle East Historic Review for Solitary Fibrous Tumor Treatment by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 166: Middle East 16-Year Perspective for Solitary Fibrous Tumor Treatment by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2014, 2025 & 2030
    • TABLE 167: Middle East Recent Past, Current & Future Analysis for Solitary Fibrous Tumor Treatment by Treatment - Surgery Treatment, Radiation Therapy Treatment and Adjuvant Chemotherapy Treatment - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 168: Middle East Historic Review for Solitary Fibrous Tumor Treatment by Treatment - Surgery Treatment, Radiation Therapy Treatment and Adjuvant Chemotherapy Treatment Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 169: Middle East 16-Year Perspective for Solitary Fibrous Tumor Treatment by Treatment - Percentage Breakdown of Value Sales for Surgery Treatment, Radiation Therapy Treatment and Adjuvant Chemotherapy Treatment for the Years 2014, 2025 & 2030
    • TABLE 170: Middle East Recent Past, Current & Future Analysis for Solitary Fibrous Tumor Treatment by End-user - Ambulatory Surgery Centers End-User, Hospitals End-User and Other End-Users - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 171: Middle East Historic Review for Solitary Fibrous Tumor Treatment by End-user - Ambulatory Surgery Centers End-User, Hospitals End-User and Other End-Users Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 172: Middle East 16-Year Perspective for Solitary Fibrous Tumor Treatment by End-user - Percentage Breakdown of Value Sales for Ambulatory Surgery Centers End-User, Hospitals End-User and Other End-Users for the Years 2014, 2025 & 2030
  • IRAN
    • TABLE 173: Iran Recent Past, Current & Future Analysis for Solitary Fibrous Tumor Treatment by Treatment - Surgery Treatment, Radiation Therapy Treatment and Adjuvant Chemotherapy Treatment - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 174: Iran Historic Review for Solitary Fibrous Tumor Treatment by Treatment - Surgery Treatment, Radiation Therapy Treatment and Adjuvant Chemotherapy Treatment Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 175: Iran 16-Year Perspective for Solitary Fibrous Tumor Treatment by Treatment - Percentage Breakdown of Value Sales for Surgery Treatment, Radiation Therapy Treatment and Adjuvant Chemotherapy Treatment for the Years 2014, 2025 & 2030
    • TABLE 176: Iran Recent Past, Current & Future Analysis for Solitary Fibrous Tumor Treatment by End-user - Ambulatory Surgery Centers End-User, Hospitals End-User and Other End-Users - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 177: Iran Historic Review for Solitary Fibrous Tumor Treatment by End-user - Ambulatory Surgery Centers End-User, Hospitals End-User and Other End-Users Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 178: Iran 16-Year Perspective for Solitary Fibrous Tumor Treatment by End-user - Percentage Breakdown of Value Sales for Ambulatory Surgery Centers End-User, Hospitals End-User and Other End-Users for the Years 2014, 2025 & 2030
  • ISRAEL
    • TABLE 179: Israel Recent Past, Current & Future Analysis for Solitary Fibrous Tumor Treatment by Treatment - Surgery Treatment, Radiation Therapy Treatment and Adjuvant Chemotherapy Treatment - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 180: Israel Historic Review for Solitary Fibrous Tumor Treatment by Treatment - Surgery Treatment, Radiation Therapy Treatment and Adjuvant Chemotherapy Treatment Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 181: Israel 16-Year Perspective for Solitary Fibrous Tumor Treatment by Treatment - Percentage Breakdown of Value Sales for Surgery Treatment, Radiation Therapy Treatment and Adjuvant Chemotherapy Treatment for the Years 2014, 2025 & 2030
    • TABLE 182: Israel Recent Past, Current & Future Analysis for Solitary Fibrous Tumor Treatment by End-user - Ambulatory Surgery Centers End-User, Hospitals End-User and Other End-Users - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 183: Israel Historic Review for Solitary Fibrous Tumor Treatment by End-user - Ambulatory Surgery Centers End-User, Hospitals End-User and Other End-Users Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 184: Israel 16-Year Perspective for Solitary Fibrous Tumor Treatment by End-user - Percentage Breakdown of Value Sales for Ambulatory Surgery Centers End-User, Hospitals End-User and Other End-Users for the Years 2014, 2025 & 2030
  • SAUDI ARABIA
    • TABLE 185: Saudi Arabia Recent Past, Current & Future Analysis for Solitary Fibrous Tumor Treatment by Treatment - Surgery Treatment, Radiation Therapy Treatment and Adjuvant Chemotherapy Treatment - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 186: Saudi Arabia Historic Review for Solitary Fibrous Tumor Treatment by Treatment - Surgery Treatment, Radiation Therapy Treatment and Adjuvant Chemotherapy Treatment Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 187: Saudi Arabia 16-Year Perspective for Solitary Fibrous Tumor Treatment by Treatment - Percentage Breakdown of Value Sales for Surgery Treatment, Radiation Therapy Treatment and Adjuvant Chemotherapy Treatment for the Years 2014, 2025 & 2030
    • TABLE 188: Saudi Arabia Recent Past, Current & Future Analysis for Solitary Fibrous Tumor Treatment by End-user - Ambulatory Surgery Centers End-User, Hospitals End-User and Other End-Users - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 189: Saudi Arabia Historic Review for Solitary Fibrous Tumor Treatment by End-user - Ambulatory Surgery Centers End-User, Hospitals End-User and Other End-Users Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 190: Saudi Arabia 16-Year Perspective for Solitary Fibrous Tumor Treatment by End-user - Percentage Breakdown of Value Sales for Ambulatory Surgery Centers End-User, Hospitals End-User and Other End-Users for the Years 2014, 2025 & 2030
  • UNITED ARAB EMIRATES
    • TABLE 191: UAE Recent Past, Current & Future Analysis for Solitary Fibrous Tumor Treatment by Treatment - Surgery Treatment, Radiation Therapy Treatment and Adjuvant Chemotherapy Treatment - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 192: UAE Historic Review for Solitary Fibrous Tumor Treatment by Treatment - Surgery Treatment, Radiation Therapy Treatment and Adjuvant Chemotherapy Treatment Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 193: UAE 16-Year Perspective for Solitary Fibrous Tumor Treatment by Treatment - Percentage Breakdown of Value Sales for Surgery Treatment, Radiation Therapy Treatment and Adjuvant Chemotherapy Treatment for the Years 2014, 2025 & 2030
    • TABLE 194: UAE Recent Past, Current & Future Analysis for Solitary Fibrous Tumor Treatment by End-user - Ambulatory Surgery Centers End-User, Hospitals End-User and Other End-Users - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 195: UAE Historic Review for Solitary Fibrous Tumor Treatment by End-user - Ambulatory Surgery Centers End-User, Hospitals End-User and Other End-Users Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 196: UAE 16-Year Perspective for Solitary Fibrous Tumor Treatment by End-user - Percentage Breakdown of Value Sales for Ambulatory Surgery Centers End-User, Hospitals End-User and Other End-Users for the Years 2014, 2025 & 2030
  • REST OF MIDDLE EAST
    • TABLE 197: Rest of Middle East Recent Past, Current & Future Analysis for Solitary Fibrous Tumor Treatment by Treatment - Surgery Treatment, Radiation Therapy Treatment and Adjuvant Chemotherapy Treatment - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 198: Rest of Middle East Historic Review for Solitary Fibrous Tumor Treatment by Treatment - Surgery Treatment, Radiation Therapy Treatment and Adjuvant Chemotherapy Treatment Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 199: Rest of Middle East 16-Year Perspective for Solitary Fibrous Tumor Treatment by Treatment - Percentage Breakdown of Value Sales for Surgery Treatment, Radiation Therapy Treatment and Adjuvant Chemotherapy Treatment for the Years 2014, 2025 & 2030
    • TABLE 200: Rest of Middle East Recent Past, Current & Future Analysis for Solitary Fibrous Tumor Treatment by End-user - Ambulatory Surgery Centers End-User, Hospitals End-User and Other End-Users - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 201: Rest of Middle East Historic Review for Solitary Fibrous Tumor Treatment by End-user - Ambulatory Surgery Centers End-User, Hospitals End-User and Other End-Users Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 202: Rest of Middle East 16-Year Perspective for Solitary Fibrous Tumor Treatment by End-user - Percentage Breakdown of Value Sales for Ambulatory Surgery Centers End-User, Hospitals End-User and Other End-Users for the Years 2014, 2025 & 2030
  • AFRICA
    • Solitary Fibrous Tumor Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2025 (E)
    • TABLE 203: Africa Recent Past, Current & Future Analysis for Solitary Fibrous Tumor Treatment by Treatment - Surgery Treatment, Radiation Therapy Treatment and Adjuvant Chemotherapy Treatment - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 204: Africa Historic Review for Solitary Fibrous Tumor Treatment by Treatment - Surgery Treatment, Radiation Therapy Treatment and Adjuvant Chemotherapy Treatment Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 205: Africa 16-Year Perspective for Solitary Fibrous Tumor Treatment by Treatment - Percentage Breakdown of Value Sales for Surgery Treatment, Radiation Therapy Treatment and Adjuvant Chemotherapy Treatment for the Years 2014, 2025 & 2030
    • TABLE 206: Africa Recent Past, Current & Future Analysis for Solitary Fibrous Tumor Treatment by End-user - Ambulatory Surgery Centers End-User, Hospitals End-User and Other End-Users - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 207: Africa Historic Review for Solitary Fibrous Tumor Treatment by End-user - Ambulatory Surgery Centers End-User, Hospitals End-User and Other End-Users Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 208: Africa 16-Year Perspective for Solitary Fibrous Tumor Treatment by End-user - Percentage Breakdown of Value Sales for Ambulatory Surgery Centers End-User, Hospitals End-User and Other End-Users for the Years 2014, 2025 & 2030

IV. COMPETITION